Upadacitinib (Rinvoq)

Ingredients: Upadacitinib
Dosage Form: Oral tablets
Innovator’s Brand Name: Rinvoq
Generic Brand Name: Upanib
Generic Manufacturer: Ziska Pharma

Indications:
Upadacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, particularly those with inadequate response or intolerance to methotrexate.

Dosage and Administration:
The recommended dose is 15 mg orally once daily; it may be administered as monotherapy or in combination with methotrexate or other non‑biologic DMARDs. Perform a complete blood count prior to initiation and adjust the dose if any hematologic parameters fall below safety thresholds.

Adverse Reactions:
Common adverse reactions include upper respiratory tract infection, nausea, cough, and fever.

Storage:
Store in a cool place below 25 °C, protected from light, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link